Contributing factors to dry eye

Article

A comparison of self-reported dry-eye symptoms after LASIK procedures in men and women

Almost nine years ago Dr Edward E. Manche had not noticed any difference in dryeye symptoms after switching from the mechanical keratome to the femtosecond laser. However, as a result of anecdotal evidence that femtosecond laser flaps during LASIK might produce a lower incidence of dry eye, Dr Manche and Dr Lilya Golas performed a comparative study to determine the truth of the matter.1

Femtosecond vs mechanical

"The outcome of the study mirrored my clinical impression between the two procedures, that there was no difference in dry eye symptoms switching between techniques," revealed Dr Manche. "The one finding that did surprise me was the difference in reported symptoms of postoperative dry eye between men and women."

The setbacks of self-diagnosis

The study was based on patient self-reporting symptoms, where each patient completed a questionnaire 1, 3, 6 and 12 months postoperatively. According to Dr Manche this self-reporting could be one of the reasons why a difference between the male and female participants was observed. He explained, "If you look at the preoperative dry-eye score between men and women, you see that women graded their reported dry-eye score as almost double that of the men. This was not surprising, as women tend to have a higher incidence of dry eye. However, postoperatively, the men had a reported dry-eye score of almost double that of women at almost every time interval."

This lower preoperative dry-eye score from the male participants could attribute to the surprising outcome. Since the baseline level of dry-eye score was lower to begin with, even a small increase in self-reported dryness might then be graded at a higher number. "This shows that additional research is needed in this area," added Dr Manche.

Dr Manche iterated that the study could have been improved and more symptoms identified if dry-eye symtoms were not self-reported. "The study could be improved by adding physical findings at the slit-lamp examination including but not limited to vital dye staining, presence of any punctate epithelial erosions, and Schirmer testing," he said.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.